Table 2.
Characteristics of Bechet’s disease patients according to the vision threatening complications
| Variable Mean ± SD or median (IQR) or N (%) | Total BD patients (n = 1094) | Non-VTBD patients (n = 545) | VTBD patients (n = 549) | P value |
|---|---|---|---|---|
| Demographic features | ||||
| Age categories | ||||
| < 30 years | 309 (28.2) | 178 (32.7) | 131 (23.9) | < 0.0001 |
| 30–40 years | 449 (41.0) | 228 (41.8) | 221 (40.3) | |
| > 40 years | 336 (30.7) | 139 (25.5) | 197 (35.9) | |
| Disease duration | 0.552 | |||
| ≤ 5 years | 486 (44.4) | 247 (45.3) | 239 (43.5) | |
| > 5 years | 608 (55.6) | 298 (54.7) | 310 (56.5) | |
| Age at onset | 0.465 | |||
| < 40 years | 570 (52.1) | 290 (53.2) | 280 (51.0) | |
| ≥ 40 years | 524 (47.9) | 255 (46.8) | 269 (49.0) | |
| Male gender | 782 (71.5) | 399 (73.2) | 383 (69.8) | 0.207 |
| Body mass index | 28.0 ± 5.5 | 27.5 ± 5.3 | 28.8 ± 5.8 | 0.067 |
| Smoking status | 0.033 | |||
| Never | 543 (58.0) | 269 (61.7) | 274 (54.8) | |
| Ever smoker | 393(42.0) | 167 (38.3) | 226 (45.2) | |
| Clinical features, N (%) | ||||
| Oral ulcers | 1094 (100) | 454 (100) | 549 (100) | – |
| Genital ulcers | 903(83.4) | 460 (85.3) | 443 (81.4) | 0.084 |
| Mucocutaneous manifestations | 586 (58.5) | 276 (55.9) | 310 (61.0) | 0.098 |
| Ocular manifestations | 812 (78.0) | 304 (59.6) | 508 (95.7) | < 0.0001 |
| Musculoskeletal manifestations | 361(34.6) | 148 (28.6) | 213 (40.5) | < 0.0001 |
| Neurological manifestations | 159 (14.9) | 63 (11.8) | 96 (18.0) | 0.005 |
| Vascular manifestations | 239 (24.5) | 120 (25.3) | 119 (23.8) | 0.608 |
| Gastrointestinal manifestations | 104 (10.6) | 42 (8.8) | 62 (12.4) | 0.065 |
| BDCAF | 4.9 ± 4.5 | 5.0 ± 3.8 | 4.8 ± 4.9 | 0.649 |
| Diabetes mellitus | 204 (21.4) | 75 (15.9) | 129 (26.9) | < 0.0001 |
| Hypertension | 265 (27.5) | 85 (17.7) | 180 (37.3) | < 0.0001 |
| Treatments, N(%) | ||||
| Colchicine | 517 (83.5) | 336 (85.3) | 181 (80.4) | 0.119 |
| Steroid dose (mg/day) | 1 (0, 62.0) | 1 (0, 45.1) | 1 (1, 41.5) | 0.867 |
| Steroid use | 855 (92.1) | 379 (84.8) | 476 (99.0) | < 0.0001 |
| Cyclosporine | 273 (26.8) | 89 (17.5) | 184 (36.1) | < 0.0001 |
| AZA | 429 (40.7) | 266 (50.5) | 163 (30.9) | < 0.0001 |
| CYC | 194 (19.4) | 105 (21.4) | 89 (17.5) | 0.115 |
| Chlorambucil | 8 (0.84) | 0 (0.0) | 7 (1.4) | – |
| Anticoagulant | 158 (15.7) | 104 (20.9) | 54 (10.6) | < 0.0001 |
| MTX | 65 (7.1) | 43 (9.7) | 22 (4.7) | 0.003 |
| Biologics | 76 (7.8) | 21 (4.5) | 55 (11.0) | < 0.0001 |
| Laboratory manifestations | ||||
| HGB (g/dl) | 12.8 ± 1.7 | 12.6 ± 1.7 | 13.3 ± 1.4 | < 0.0001 |
| TLC (× 103/mm3) | 8.0 ± 3.1 | 8.0 ± 3.2 | 8.1 ± 2.9 | 0.860 |
| PLT (× 103/mm3) | 263.9 ± 80.5 | 272.0 ± 86.5 | 250.5 ± 67.8 | 0.001 |
| ESR (mm/1sthr) | 30.0 ± 20.5 | 31.1 ± 20.9 | 29.0 ± 20.1 | 0.107 |
| CRP titre (mg/L) | 8 (0, 96) | 9.2 (0, 96) | 6.9 (0, 55.3) | < 0.0001 |
| SUA | 4.8 ± 1.6 | 4.7 ± 1.4 | 5.0 ± 1.4 | 0.247 |
BDCAF, Behçets disease current activity form; HGB, hemoglobin; TLC, total leucocyte count; PLT, platelet count; ESR, erythrocyte sedimentation rate; CR, C-reactive protein; SUA, serum uric acid